947 EFFICACY AND SAFETY OF UPADACITINIB FOR THE TREATMENT OF FISTULAS AND FISSURES IN PATIENTS WITH CROHN'S DISEASE
Jean‐Frédéric Colombel(Mount Sinai Hospital), Walter Reinisch(Medical University of Vienna), Florian Rieder(Cleveland Clinic), Xuan Zhu(U.S. National Science Foundation), Peter M. Irving(Guy's and St Thomas' NHS Foundation Trust), Elena Dubcenco(AbbVie (United States)), David A. Schwartz(St. Jude Children's Research Hospital), Feng Tian(Sun Yat-sen University), Patrick Hecht, Ryohei Hayashi, Ana P. Lacerda(AbbVie (United States)), Sofie Berg(AbbVie (United States)), Elena Marced, Remo Panaccione(University of Calgary)
Cited by 2
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k